EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access

Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial

Brandan K Penaluna, Jennifer L Vande Voort, William V Bobo, Vanessa Pazdernik, Eric D Achtyes, Fernando S Goes, John F Greden, Sagar V Parikh, Mark A Frye, Balwinder Singh

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.119414 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Brandan K Penaluna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: penaluna.brandan@mayo.edu. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Ketamine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous work has identified four correlated factors (depression phenotypes) using the Montgomery-Åsberg Depression Rating Scale (MADRS)- Sadness, Negative Thoughts, detachment/Interest and Activity (IA), and Neurovegetative. We explored treatment responses to ketamine based on these 4 phenotypes in treatment resistant depression (TRD). METHODS: This is a secondary analysis of data from an open-label multi-center, clinical trial (BioK) examining biomarkers of treatment response, that enrolled 75 patients (ages 18-65 years old) with treatment-resistant unipolar or bipolar depression, excluding those with an active substance use disorder, psychosis, and unstable medical conditions. Pre-existing treatments were continued. Participants received 3 IV ketamine infusions over an 11-day period (acute phase). Depressive symptoms were measured using MADRS, with the four phenotypes assigned as positive or negative based on the total subset MADRS score. Change in depressive symptoms and odds of remissions (MADRS

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsMajor Depressive DisorderDepressive Disorder, Treatment-ResistantKetamineAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultPhenotypePsychiatric Status Rating ScalesTreatment OutcomeSecondary Data Analysis

Stichwörter der Autor:innen

Bio-KKetaminePhenotypesTreatment-resistant depression

Substanzen

Antidepressive AgentsKetamine

Autor:innen und Institutionen

  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: penaluna.brandan@mayo.edu.
  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
  • Department of Behavioral Science & Social Medicine, Florida State University College of Medicine, Tallahassee, FL, United States of America.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
  • Department of Psychiatry, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States of America.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Georgia Clinical and Translational Science Alliance

Zitieren

APA

Penaluna, B. K., Vande Voort, J. L., Bobo, W. V., Pazdernik, V., Achtyes, E. D., Goes, F. S., Greden, J. F., Parikh, S. V., Frye, M. A., & Singh, B. (2025). Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119414

Vancouver

Penaluna BK, Vande Voort JL, Bobo WV, Pazdernik V, Achtyes ED, Goes FS, et al. Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119414

BibTeX
@article{Penaluna2025,
  author = {Penaluna, Brandan K and Vande Voort, Jennifer L and Bobo, William V and Pazdernik, Vanessa and Achtyes, Eric D and Goes, Fernando S and Greden, John F and Parikh, Sagar V and Frye, Mark A and Singh, Balwinder},
  title = {Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.119414}
}
Kostenlos starten →